12:00 AM
 | 
Jan 03, 2011
 |  BC Week In Review  |  Company News  |  Deals

Forest Laboratories, Gruenenthal deal

Forest's Forest Healthcare B.V. subsidiary acquired from Gruenenthal its rights to antibiotic colistin and reacquired rights to Colobreathe colistimethate sodium to treat bacterial infections in patient with cystic fibrosis (CF). Gruenenthal, which currently markets colistin for the indication...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >